TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03629002

Intervention type: BIOLOGICAL
Intervention: Study of the gene expression profile
Description: qPCR analysis

Intervention type: BIOLOGICAL
Intervention: Study of the gene expression profile
Description: qPCR analysis
Study: NCT02133677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide 100mg
Description: WBRT: 30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week) CT: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks
Study: NCT03008408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study: NCT04214392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)
Description: Given via ICT delivery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)
Description: Given via ICT/ICV dual delivery
Study: NCT02310321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Once-daily oral administration on 14 consecutive days in every cycle in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Once-daily oral administration on 14 consecutive days in every cycle in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Once-daily oral administration on 14 consecutive days in every cycle in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Induction period: Once-daily intravenous injection of 12 mg/m\^2 idarubicin on 3 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Induction period: Once-daily intravenous injection of 12 mg/m\^2 idarubicin on 3 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Induction period: Once-daily intravenous injection of 12 mg/m\^2 idarubicin on 3 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction period: Once-daily intravenous injection of 100 mg/m\^2 cytarabine on 7 consecutive days.~Consolidation period: Twice-daily intravenous injection of 1.5 g/m\^2 cytarabine on Days 1, 3, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction period: Once-daily intravenous injection of 100 mg/m\^2 cytarabine on 7 consecutive days.~Consolidation period: Twice-daily intravenous injection of 1.5 g/m\^2 cytarabine on Days 1, 3, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction period: Once-daily intravenous injection of 100 mg/m\^2 cytarabine on 7 consecutive days.~Consolidation period: Twice-daily intravenous injection of 1.5 g/m\^2 cytarabine on Days 1, 3, and 5.
Study: NCT00339365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships Program
Description: Participants assigned to PFR will receive ten weekly home visits that will focus on promoting the development of a secure attachment between foster parents and infants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Education Support Program
Description: EES will consist of three monthly home visits, during which infants will be assessed and referred for additional care if necessary. EES participants will not receive any training.
Study: NCT04044794

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care includes standardized educational materials to promote self-management of body weight along with provision of $60 for participants to purchase supplies or equipment to facilitate weight management.
Study: NCT03635866

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluciclovine PET/MRI
Description: It is unknown how many negative MRFTBs of PI-RADS 4 lesions are false negative biopsies or false positive tests.
Study: NCT03002857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA-C
Description: LMA-C will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baska Mask
Description: Baska Mask will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel
Description: I-gel LMA placement will be done as suggested in supine position with a standard gel pillow under patients head.
Study: NCT03024411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPod (Music/video games)
Description: Experimental patients will be given an iPod to enjoy music/video games during induction of labor.
Study: NCT02672605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pennsylvania State Abortion Consent
Description: Measuring the level of stigma felt pre- or post-exposure to the abortion consent language.
Study: NCT01314248

Intervention type: DEVICE
Intervention: each child will receive both the LMA and ILA
Description: each child will receive both the size 2 LMA and size 1.5 ILA
Study: NCT00842465

Intervention type: BIOLOGICAL
Intervention: blood collection for hormonal status analysis
Description: for hormonal status analysis

Intervention type: BIOLOGICAL
Intervention: blood collection for hormonal status analysis
Description: for hormonal status analysis

Intervention type: BIOLOGICAL
Intervention: blood collection for hormonal status analysis
Description: for hormonal status analysis

Intervention type: PROCEDURE
Intervention: breast Biopsy or surgery
Description: breast Biopsy or surgery

Intervention type: PROCEDURE
Intervention: breast Biopsy or surgery
Description: breast Biopsy or surgery

Intervention type: GENETIC
Intervention: blood collection
Description: blood collection for prlR gene sequencing

Intervention type: GENETIC
Intervention: blood collection
Description: blood collection for prlR gene sequencing

Intervention type: GENETIC
Intervention: blood collection
Description: blood collection for prlR gene sequencing

Intervention type: OTHER
Intervention: ultrasonography (pelvis and breast), bone mineral density
Description: ultrasonography (pelvis and breast), bone mineral density

Intervention type: OTHER
Intervention: ultrasonography (pelvis and breast), bone mineral density
Description: ultrasonography (pelvis and breast), bone mineral density
Study: NCT01137565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 853
Description: Single dose administration of AMG 853 or placebo in tablet form to adolescent and adult subjects with asthma

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to AMG 853
Study: NCT01790308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII
Description: continuous subcutaneous insulin infusion for 2\~4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: CSII for 2\~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months
Study: NCT01278641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded strength resistance training program
Description: Graded strength resistance training, 75 minutes, twice a week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Temperate pool exercise program
Description: Temperate pool low intensive exercise, 50 minutes, twice a week for 12 weeks.
Study: NCT01931449

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified method of digestive tract reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine digestive tract reconstruction
Study: NCT04385251

Intervention type: OTHER
Intervention: Data Collection
Description: DATA COLLECTION AT ENROLLMENT:~Demographics; Symptoms and health status; Co-morbidities; Targeted medications; Specimen Collection (substudy at selected sites): Upper respiratory swab, blood for serum storage.~DATA COLLECTION AT DAYS 7, 14 \& 28:~Vital and hospitalization status; Symptoms and health status
Study: NCT01897064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Psychiatric Treatment
Description: Standard psychiatric treatment.
Study: NCT00526136

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant (oral)
Description: Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant (oral)
Description: Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant (oral)
Description: Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)
Study: NCT02146690

Intervention type: OTHER
Group type: OTHER
Intervention: osteopathic manipulative treatment

Intervention type: OTHER
Group type: OTHER
Intervention: sham therapy

Intervention type: OTHER
Group type: OTHER
Intervention: usual care

Intervention type: OTHER
Group type: OTHER
Intervention: usual care

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Study: NCT01285505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam commercial sublingual formulation
Description: 0.5 mg tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam test sublingual tablet
Description: 0.5 mg tablet, single dose
Study: NCT01875055

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS and Algorithm
Description: NIRS cerebral oximetry will be used to guide the use of an algorithm based on the modification of previously defined important physiologic variables will be initiated to reverse the desaturation (beginning when the saturation drops at least 10% from the baseline) that occur in the ICU

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS derived cerebral oximetry
Description: NIRS sensors will be placed the forehead of the patient but NIRS derived data will be blinded to the ICU caregivers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS derived cerebral oximetry
Description: NIRS sensors will be placed the forehead of the patient but NIRS derived data will be blinded to the ICU caregivers
Study: NCT01714284

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Informative
Description: The intervention consists in a simple informative counseling about the utility of weight loss for clinical control of psoriatic disease.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: The intervention consists in a 20 weeks quantitative and qualitative dietary plan for weight loss associated with physical exercise. The plan will be developed with the help of qualified staff (Dieticians) and elaborated in relation to individual needs of the patient.
Study: NCT05549687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Participate in Pack Health, an electronic support program

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Access to telephone triage line for support care services
Study: NCT01596127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Rituximab
Description: Phase I: Starting dose Rituximab 10 mg intrathecally twice weekly until 2 consecutive CSF samples are negative for the presence of blast cells. Thereafter, rituximab 10 mg intrathecally weekly for additional 4 weeks, followed by intrathecal rituximab 10 mg administered once every other week for an additional 8 weeks.~Phase II Starting Dose of Rituximab: Maximum tolerated dose from Phase I.
Study: NCT03236805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Initial bolus of 20 mg (around 0.3 mg per kg) followed by bolus of 10 mg every 5 minutes as reported by the recommandations of experts of the french society of urgency care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Bolus of 2 mg (patient with weight under 60 kgs) or bolus of 3 mg (patient with weight above 60 kgs) every 5 minutes as reported by the recommandations of experts of the french society of urgency care
Study: NCT03150888

Intervention type: DRUG
Intervention: Antihypertensive Agents
Description: Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.

Intervention type: DRUG
Intervention: Antihypertensive Agents
Description: Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.

Intervention type: OTHER
Intervention: Cardiovascular risk factors
Description: Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.

Intervention type: OTHER
Intervention: Cardiovascular risk factors
Description: Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.
Study: NCT04652999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Relaxation with Guided Imagery
Description: Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot). The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds. The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Guided Imagery
Description: This placebo consists on neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, be it positive or negative, which occurred before patient has the current DFU. Then, questions are asked which allow a more detailed reconstruction of the event and the patient is asked to imagine according only to the instructions given. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered in each of the questions given.
Study: NCT00233168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Program
Description: 14 counseling sessions focusing on INH adherence conducted over 6 months, starting once per week and decreasing in frequency to once a month.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life Skills and Self-Esteem Training Program (Attention Control Arm)
Description: Peer counseling session covering life skills (e.g., communication skills, goal setting, self-esteem) training, 14 sessions over 6 months beginning once per week and decreasing in frequency over time to once per month.
Study: NCT01883375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity Talk
Description: Patient and family member participants will be given the Dignity Talk framework questions and asked to use them in conversation with each other. Research nurse will return at day 4-6 to confirm both participants have covered all items they wish to discuss. 4-6 months after the death of patient, family members will be contacted in order to collect data pertaining to their bereavement experiences and distress. Will also be asked to complete evaluative feedback on Dignity Talk.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Dignity Talk Communication Topics
Description: There have not been any non-completers - this arm not being used currently
Study: NCT01723280

Intervention type: DRUG
Intervention: Oxygen
Description: During and 2 hrs after surgery

Intervention type: DRUG
Intervention: Oxygen
Description: During and 2 hrs after surgery
Study: NCT03828318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Activation Booklet and nursing support for patients with LARS
Description: The LARS Patient-Centered Program will consist of an educational booklet and nursing support made available only to patients randomized to the intervention group.
Study: NCT02569827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celgosivir
Description: Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg celgosivir total).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modipafant 50mg
Description: Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg modipafant)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Q6H for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modipafant 100mg
Description: Modipafant 100 mg Q12H alternating with placebo Q12H for 5 days (total of modipafant 10 doses = 1000 mg modipafant)
Study: NCT02425527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The rehabilitation gaming
Description: The web-based cognitive training platform CogniFit includes about 33 mini games designed with the purpose of improving the user's cognitive abilities as brain exercises. For the purpose of the research, a selection of CogniFit mini games will be included in the intervention. The mini game tasks will be adapted to players' skills getting more difficult as the players progress. The game tasks are targeting different cognitive abilities such as memory, visual-spatial ability, attention, tracking and fast decision making.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The entertaining gaming
Description: The gameplay will consist of these main elements: 1) the player will be playing the main character of the game, 2) the character will be presented for the player from an isometric perspective, 3) the player will control the character by navigating in partly open-ended 3D environments in which the player must decide a direction and move towards it by avoiding obstacles; 4) the player will engage with real-time action events and act quickly by making strategic and tactical decisions; 5) the player must memorize locations, characters, dialogue and tasks; as well as 6) track, follow or aim at several objects simultaneously. Gaming requires also patience as participants can only make progress in games by trial and error.
Study: NCT03894137

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grains of Paradise (Aframomum Melegueta)
Description: This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Grains of Paradise (Aframomum Melegueta)
Description: This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism
Study: NCT02062346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123
Description: Intravenous infusion of BQ123 ( selective ETA antagonist )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123/788
Description: or BQ123/788 (mixed ETA/B antagonists)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of saline
Study: NCT04872647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-Based Health Coaching Utilizing Lifestyle Action Plans
Description: Culturally sensitive health coaches trained in motivational interviewing provide 10-20 minutes of weekly phone-based health coaching. They not only guide the patient in creating a SMART goal, but assess and build off of the previous weeks' goal and problem-solve with the patient. During the week, the coach and patient text regarding daily blood glucose monitoring with real-time feedback and coaching about the implementation of the patients' goal.
Study: NCT00752115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: 50mg, day1,8 and 15 in each cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tab, day 1,8 and 15 in each cycle.
Study: NCT01834378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity intervention
Description: We administer, a pedometer and the participants receive a prescription on physical exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity intervention.
Description: We schedule group sessions for changes in behavior e.g. type of physical activity to prefer, barriers for change of life style etc.
Study: NCT03400787

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Latera Implant
Description: Treatment with implant
Study: NCT00752115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel (taxol)
Description: paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
Study: NCT03400787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Sham procedure where the Latera delivery device is inserted but no implant delivered.
Study: NCT00752115

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel (taxol)
Description: paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin (palaplatin)
Description: carboplatin; AUC=6 on day 1, every 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin (palaplatin)
Description: carboplatin; AUC=6 on day 1, every 28 days
Study: NCT02565927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional airway stent
Description: process airway stenting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional airway stent
Description: process airway stenting
Study: NCT06571604

Intervention type: DIAGNOSTIC_TEST
Intervention: Dislocation
Description: One episode of total hip dislocation diagnozied on Xray within 2 years of surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: No dislocation
Description: No experience of dislocation within two years post-surgery